|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
"Double-Hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression.
|
20660329 |
2010 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD20 is expressed in most B-cell lymphomas and is a critical molecular target of rituximab.
|
24147568 |
2014 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma.
|
26880268 |
2016 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD20 is an important target for molecularly targeted therapy for a subset of B-cell lymphomas.
|
28618063 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD20 is the first-line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias.
|
29079175 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD20 antibody-loaded CD20<sup>+</sup> B-cell lymphoma cell lines were cultured with NK cells and ADCC activity was determined by lactate dehydrogenase release assays.
|
30132083 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD20 expression by malignant lymphocyte-predominant cells, a tendency for late relapses, and the risk of transformation to aggressive large B-cell lymphoma are characteristic features with important implications for treatment and follow-up.
|
30485408 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
All 11 BCLs presented positive staining for CD20 and CD79a but negative for other antibodies.
|
16360416 |
2006 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
ALT-803 represents a novel immunostimulatory drug that enhances NK-cell antilymphoma responses in vitro and in vivo, thereby supporting the clinical investigation of ALT-803 plus anti-CD20 mAbs in patients with indolent B-cell lymphoma.
|
26423796 |
2016 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Although only two cases showed immunohistochemical evidence of B-cell lineage (CD20+), all five cases were documented as B-cell lymphomas on the basis of the clonal immunoglobulin heavychain gene rearrangement, as demonstrated by polymerase chain reaction (PCR) in all the cases and by Southern blot hybridization in three cases; all cases were negative for T-cell markers, and three cases showed germline configuration for T-cell receptor beta-chain.
|
8772789 |
1996 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Although rituximab is a critical monoclonal antibody therapy for CD20-positive B-cell lymphomas, rituximab resistance showing a CD20-negative phenotypic change has been a considerable clinical problem.
|
19769942 |
2009 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Among 840 consecutive patients with CD20-positive B-cell lymphoma who received rituximab-based chemotherapy from 2003 through 2014 at Seoul National University Hospital, 732 patients were excluded because either anti-HBc was not assessed or they were HBsAg-seropositive.
|
26531242 |
2016 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation.
|
10808158 |
2000 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD20-IFNα also abolished checkpoint blockade resistance in advanced B-cell lymphoma.
|
28533311 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
|
30483893 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD20Fab-LDM exerted potent cytotoxicity against CD20+ B-cell lymphoma cell lines in vitro (IC50: 10-30 pM) and in the Raji xenograft model.
|
20463754 |
2010 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Burkitt lymphoma (BL) is an aggressive B-cell neoplasm that is currently treated by intensive chemotherapy in combination with anti-CD20 antibodies.
|
28064214 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
CD107a degranulation and intracellular IFNγ production were also enhanced in CAR(+) exPBNK in response to CD20(+) B-NHL -: specific stimulation.
|
25492700 |
2015 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD52 and CD20 are co-expressed on the cell surface of malignant B cells in B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL) and increased expression of both antigens is detected on dividing or recently divided cells ("proliferative fraction") in CLL.
|
30145356 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Combination treatment with 4-1BBL/anti-CD20 fusion protein and anti-CD3/anti-CD20 diabody led to significantly increased T-cell cytotoxicity to human B-lymphoma cells in vitro and drastically more potent tumor inhibitory activity in vivo in xenografted B-cell lymphoma in severe combined immunodeficiency disease mice.
|
20463597 |
2010 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment.
|
22500644 |
2012 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
|
20631068 |
2010 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
|
26195067 |
2015 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite wide use of the anti-CD20 monoclonal antibody rituximab in the treatment of B cell lymphomas, the mechanism by which it causes B cell depletion remains a subject of controversy.
|
12571855 |
2003 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite widespread use of the anti-CD20 monoclonal antibody (mAb), rituximab, in treating B-cell lymphomas, its efficacy remains variable and often modest.
|
19828699 |
2009 |